LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Envista Holdings Corp

Fermé

SecteurSoins de santé

28.97 0.84

Résumé

Variation du prix de l'action

24h

Actuel

Min

28.89

Max

29.06

Chiffres clés

By Trading Economics

Revenu

63M

33M

Ventes

81M

751M

P/E

Moyenne du Secteur

104.857

121.746

BPA

0.38

Marge bénéficiaire

4.383

Employés

12,300

EBITDA

-23M

73M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-1.62% downside

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1B

4.9B

Ouverture précédente

28.13

Clôture précédente

28.97

Sentiment de l'Actualité

By Acuity

50%

50%

127 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Envista Holdings Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 févr. 2026, 23:21 UTC

Acquisitions, Fusions, Rachats

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 févr. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 févr. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 févr. 2026, 23:06 UTC

Résultats

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 févr. 2026, 23:04 UTC

Résultats

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 févr. 2026, 23:04 UTC

Résultats

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 févr. 2026, 23:01 UTC

Résultats

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 févr. 2026, 23:01 UTC

Résultats

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 févr. 2026, 22:52 UTC

Acquisitions, Fusions, Rachats

Qube Shareholders to Receive A$5.20/Share in Cash

15 févr. 2026, 22:52 UTC

Acquisitions, Fusions, Rachats

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 févr. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 févr. 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 févr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 févr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 févr. 2026, 20:48 UTC

Résultats

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 févr. 2026, 20:47 UTC

Résultats

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 févr. 2026, 20:46 UTC

Résultats

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 févr. 2026, 20:45 UTC

Résultats

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 févr. 2026, 20:44 UTC

Résultats

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 févr. 2026, 20:44 UTC

Résultats

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 févr. 2026, 20:43 UTC

Résultats

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 févr. 2026, 20:42 UTC

Résultats

BlueScope Net Debt A$2.2 Million at Dec. 31

15 févr. 2026, 20:42 UTC

Résultats

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 févr. 2026, 20:41 UTC

Résultats

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 févr. 2026, 20:40 UTC

Résultats

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 févr. 2026, 20:40 UTC

Résultats

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 févr. 2026, 20:39 UTC

Résultats

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparaison

Variation de prix

Envista Holdings Corp prévision

Objectif de Prix

By TipRanks

-1.62% baisse

Prévisions sur 12 Mois

Moyen 28.5 USD  -1.62%

Haut 35 USD

Bas 19 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

7

Achat

7

Maintien

0

Vente

Score Technique

By Trading Central

15.98 / N/ASupport & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

127 / 351Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Envista Holdings Corp

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
help-icon Live chat